Receive our newsletter – data, insights and analysis delivered to you
July 1, 2009

AstraZeneca Receives European Authorisation for IRESSA Cancer Drug

AstraZeneca's oral anti-cancer drug Iressa has been granted marketing authorisation by the European Commission. Iressa is used for the treatment of adults with locally advanced or metastatic non-small cell lung cancer, with activating mutations of EGFR-TK across all lines of therapy.

By cms admin

AstraZeneca’s oral anti-cancer drug Iressa has been granted marketing authorisation by the European Commission.

Iressa is used for the treatment of adults with locally advanced or metastatic non-small cell lung cancer, with activating mutations of EGFR-TK across all lines of therapy.

The authorisation by the European Commission was based on submissions including two pivotal Phase III studies that compared Iressa with chemotherapy, IPASS and Interest.

AstraZeneca executive vice-president for development Anders Ekblom said that Iressa is the first targeted treatment for lung cancer, and the EU marketing authorisation represents an important step forward in the treatment of this devastating disease.

“For the first time, patients with EGFR mutation positive tumours will have a more effective and better-tolerated alternative to chemotherapy as a first-line treatment,” Ekblom said.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU